Overview

Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

Status:
RECRUITING

Trial end date:
2029-07-01

Target enrollment:

Participant gender:

Summary

A randomized, multicenter, Phase III trial evaluating the efficacy and safety of first-line Sequential AG-mFOLFOX chemotherapy combined with Serplulimab and Bevacizumab versus AG chemotherapy alone in advanced pancreatic cancer. The primary endpoint is Overall Survival (OS). Approximately 292 patients will be enrolled in China.

Phase:

PHASE3

Details

Lead Sponsor:

Zhejiang Cancer Hospital

Treatments:

Bevacizumab